Revenues fall at Sensodyne maker Haleon after weaker painkiller sales
Shares were lower in early trading on Thursday as a result.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Consumer healthcare firm Haleon has revealed a surprise dip in revenues for the latest quarter as it was impacted by weaker sales of painkillers.
Shares in the Sensodyne and Voltaren maker were lower in early trading on Thursday as a result.
Haleon told investors that revenues declined by 0.6% to £2.78 billion for the three months to September 30, compared with the same period last year.
It came as the company revealed sales in its pain relief business dropped by 1.3% to £628 million for the period.
The group said it was impacted by mid-single digit decline for Panadol, while Voltaren sales were broadly flat.
Total revenues were also impacted by the sale of some of its non-core brands over the past year, including ChapStick which it sold to private equity firm Yellow Wood Partners.
Having achieved organic revenue and organic profit growth of 4.4% and 9.7% respectively year-to-date, we are well on track to deliver our full-year 2024 guidance
Nevertheless, the group saw organic revenues rise by 6.1% for the quarter, supported by a 3.3% increase in pricing.
It said its biggest brands helped drive a 5.4% rise in organic revenues, highlighting particularly strong performances from Sensodyne, Parodontax and Advil.
Meanwhile, organic profits grew by 7.4% for the quarter.
Chief executive Brian McNamara said: “Third quarter trading was strong with momentum across the business underpinned by the strength of our brand portfolio driving market share gains.
“Oral health was again a particular highlight, with organic revenue up high-single digit as Sensodyne and Parodontax continued to drive growth.
“Having achieved organic revenue and organic profit growth of 4.4% and 9.7% respectively year-to-date, we are well on track to deliver our full-year 2024 guidance.”
Shares in the company were down 2.3% in early trading.